Prothena Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.02.21	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04.02.21	Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th (GlobeNewswire)
02.02.21	ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch (RTTNews)
01.02.21	Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA (GlobeNewswire)
09.12.20	Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis (GlobeNewswire)
04.12.20	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04.11.20	Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update (GlobeNewswire)
04.11.20	Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020 (GlobeNewswire)
28.10.20	Prothena to Report Third Quarter 2020 Financial Results on November 4 (GlobeNewswire)
21.10.20	Roche, Prothena To Advance Prasinezumab Into Phase 2b Study In Parkinson's Disease - Quick Facts (RTTNews)
20.10.20	Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease (GlobeNewswire)
02.10.20	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
15.09.20	Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress (GlobeNewswire)
11.09.20	Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study (GlobeNewswire)
08.09.20	Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15 (GlobeNewswire)
03.09.20	Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders (GlobeNewswire)
02.09.20	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06.08.20	Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update (GlobeNewswire)
05.08.20	Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders (GlobeNewswire)
30.07.20	Prothena to Report Second Quarter 2020 Financial Results on August 6 (GlobeNewswire)
27.05.20	Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3 (GlobeNewswire)
06.05.20	Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance (GlobeNewswire)
29.04.20	Prothena to Report First Quarter 2020 Financial Results on May 6 (GlobeNewswire)
24.04.20	Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19 (GlobeNewswire)
23.04.20	IMMU Gets Early FDA Nod, KNSA's PN Trial Meets Goals, MYOV In Good Spirits (RTTNews)
22.04.20	Stock Alert: Prothena Down As Mid-stage Study Of Prasinezumab Fails (RTTNews)
22.04.20	Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease (GlobeNewswire)
03.04.20	Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03.03.20	Prothena Announces Appointment of Brandon Smith as Chief Business Officer (GlobeNewswire)
12.02.20	Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update (GlobeNewswire)
05.02.20	Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12 (GlobeNewswire)
05.12.19	Prothena Announces Appointment of Oleg Nodelman to its Board of Directors (GlobeNewswire)
05.11.19	Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update (GlobeNewswire)
29.10.19	Prothena to Report Third Quarter 2019 Financial Results on November 5 (GlobeNewswire)
28.08.19	6 Top Gainers In Healthcare Sector (PSTV, PRTA, ARDS…) (RTTNews)
06.08.19	Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update (GlobeNewswire)
30.07.19	Prothena to Report Second Quarter 2019 Financial Results on August 6 (GlobeNewswire)
01.07.19	Prothena Announces Appointment of Paula K. Cobb to its Board of Directors (GlobeNewswire)
30.05.19	Prothena to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
07.05.19	Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update (GlobeNewswire)
30.04.19	Prothena to Report First Quarter 2019 Financial Results on May 7 (GlobeNewswire)
18.04.19	Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis (GlobeNewswire)
05.03.19	Prothena to Participate in Upcoming March Healthcare Conferences (GlobeNewswire)
14.02.19	Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update (GlobeNewswire)
04.02.19	Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14 (GlobeNewswire)
06.11.18	Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update (GlobeNewswire)
30.10.18	Prothena to Report Third Quarter 2018 Financial Results on November 6 (GlobeNewswire)
07.08.18	Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update (GlobeNewswire)
31.07.18	Prothena to Report Second Quarter 2018 Financial Results on August 7 (GlobeNewswire)
25.06.18	Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Prothena Corporation PLC

Aktien Top/Flop

Meistgelesene Nachrichten